RU2385161C2 - Способ лечения болезни альцгеймера - Google Patents

Способ лечения болезни альцгеймера Download PDF

Info

Publication number
RU2385161C2
RU2385161C2 RU2005134351/15A RU2005134351A RU2385161C2 RU 2385161 C2 RU2385161 C2 RU 2385161C2 RU 2005134351/15 A RU2005134351/15 A RU 2005134351/15A RU 2005134351 A RU2005134351 A RU 2005134351A RU 2385161 C2 RU2385161 C2 RU 2385161C2
Authority
RU
Russia
Prior art keywords
peptide
disease
seq
antibody
amyloid
Prior art date
Application number
RU2005134351/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2005134351A (ru
Inventor
БАРРИО Мануэль САРАСА (ES)
БАРРИО Мануэль САРАСА
Original Assignee
Араклон Байотек, С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Араклон Байотек, С.Л. filed Critical Араклон Байотек, С.Л.
Publication of RU2005134351A publication Critical patent/RU2005134351A/ru
Application granted granted Critical
Publication of RU2385161C2 publication Critical patent/RU2385161C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
RU2005134351/15A 2003-05-08 2004-05-03 Способ лечения болезни альцгеймера RU2385161C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301054A ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
ESP200301054 2003-05-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2009148539/15A Division RU2526155C2 (ru) 2003-05-08 2009-12-25 Способ лечения болезни альцгеймера

Publications (2)

Publication Number Publication Date
RU2005134351A RU2005134351A (ru) 2006-04-27
RU2385161C2 true RU2385161C2 (ru) 2010-03-27

Family

ID=32982086

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2005134351/15A RU2385161C2 (ru) 2003-05-08 2004-05-03 Способ лечения болезни альцгеймера
RU2009148539/15A RU2526155C2 (ru) 2003-05-08 2009-12-25 Способ лечения болезни альцгеймера

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2009148539/15A RU2526155C2 (ru) 2003-05-08 2009-12-25 Способ лечения болезни альцгеймера

Country Status (19)

Country Link
US (6) US20090162362A1 (enExample)
EP (5) EP2356996B9 (enExample)
JP (5) JP2006525288A (enExample)
CN (2) CN101264326A (enExample)
AT (1) ATE435024T1 (enExample)
AU (2) AU2004237373A1 (enExample)
BR (1) BRPI0410684A (enExample)
CA (1) CA2524571C (enExample)
CY (1) CY1109454T1 (enExample)
DE (1) DE602004021797D1 (enExample)
DK (3) DK2356996T5 (enExample)
ES (6) ES2246177B1 (enExample)
IL (8) IL171651A (enExample)
MX (1) MXPA05010914A (enExample)
PL (3) PL2075007T3 (enExample)
PT (3) PT2356996E (enExample)
RU (2) RU2385161C2 (enExample)
SI (1) SI1623719T1 (enExample)
WO (1) WO2004098631A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2567808C2 (ru) * 2010-07-14 2015-11-10 Мерк Шарп Энд Домэ Корп. Моноклональное антитело против addl и его применения
RU2607368C2 (ru) * 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
RU2712750C1 (ru) * 2016-02-15 2020-01-31 Араклон Байотек, С.Л. Амилоидный конъюгат, его применения и способы

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
JP5419131B2 (ja) * 2005-12-12 2014-02-19 エーシー イミューン ソシエテ アノニム 治療的特性を有するβ１〜４２特異的モノクローナル抗体
TWI551607B (zh) * 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CA2701793C (en) * 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
RU2542967C2 (ru) * 2007-10-05 2015-02-27 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
EP2258398A1 (en) * 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
JP5745531B2 (ja) 2009-12-11 2015-07-08 アラクロン・ビオテック・エセ・エレ アミロイドベータペプチドの検出を改善するための方法および試薬
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750349A (en) * 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
AU5525090A (en) * 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
JP2980677B2 (ja) 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CA2340394A1 (en) * 1998-08-20 2000-03-02 Jorge R. Barrio Methods for labeling .beta.-amyloid plaques and neurofibrillary tangles
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CA2500462A1 (en) * 2001-12-26 2004-03-25 Universidad De Zaragoza Polyclonal antibodies, preparation method thereof and use of same
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
ES2201929B1 (es) * 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
MXPA05003621A (es) * 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
PL378571A1 (pl) * 2003-02-01 2006-05-02 Neuralab Limited Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750349A (en) * 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEZLIN R.S. Structure and biosynthesis of antibodies. - Moscow: Nauka,p.156-159, 1972. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2567808C2 (ru) * 2010-07-14 2015-11-10 Мерк Шарп Энд Домэ Корп. Моноклональное антитело против addl и его применения
RU2607368C2 (ru) * 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
RU2712750C1 (ru) * 2016-02-15 2020-01-31 Араклон Байотек, С.Л. Амилоидный конъюгат, его применения и способы

Also Published As

Publication number Publication date
IL207875A (en) 2013-02-28
PL2075007T3 (pl) 2013-09-30
AU2011200170A1 (en) 2011-02-03
AU2004237373A1 (en) 2004-11-18
EP2356996A1 (en) 2011-08-17
IL207878A (en) 2013-02-28
PT2075007E (pt) 2013-08-23
JP2016065100A (ja) 2016-04-28
US20200140488A1 (en) 2020-05-07
CN101264326A (zh) 2008-09-17
US20110262458A1 (en) 2011-10-27
JP2018119011A (ja) 2018-08-02
ES2423590T3 (es) 2013-09-23
US20210214394A1 (en) 2021-07-15
IL207878A0 (en) 2011-07-31
PL1623719T3 (pl) 2010-11-30
RU2526155C2 (ru) 2014-08-20
US20170260234A1 (en) 2017-09-14
EP2075007A3 (en) 2009-11-11
CA2524571A1 (en) 2004-11-18
EP2075007B1 (en) 2013-05-22
RU2009148539A (ru) 2011-06-27
US20140044725A1 (en) 2014-02-13
SI1623719T1 (sl) 2009-12-31
MXPA05010914A (es) 2006-03-21
ES2246177A1 (es) 2006-02-01
IL207876A (en) 2013-03-24
JP2012006967A (ja) 2012-01-12
CY1109454T1 (el) 2014-08-13
EP1623719A1 (en) 2006-02-08
CN1784240A (zh) 2006-06-07
ES2246177B1 (es) 2007-03-01
PT1623719E (pt) 2009-10-08
BRPI0410684A (pt) 2006-06-20
EP1623719B1 (en) 2009-07-01
EP2305286A2 (en) 2011-04-06
IL171651A (en) 2011-11-30
US20090162362A1 (en) 2009-06-25
IL207877A0 (en) 2011-07-31
IL207880A0 (en) 2011-07-31
EP2075007B9 (en) 2013-09-04
ATE435024T1 (de) 2009-07-15
IL207880A (en) 2013-02-28
RU2005134351A (ru) 2006-04-27
EP2082747A3 (en) 2010-01-13
DK2075007T3 (da) 2013-07-29
DK2356996T3 (da) 2013-07-22
IL207879A (en) 2013-02-28
IL207881A (en) 2013-02-28
WO2004098631A1 (es) 2004-11-18
EP2305286A3 (en) 2011-11-09
IL207879A0 (en) 2011-07-31
JP2014129389A (ja) 2014-07-10
CA2524571C (en) 2017-01-10
EP2356996B9 (en) 2013-08-28
ES2329369T3 (es) 2009-11-25
AU2011200170C1 (en) 2012-03-22
IL207876A0 (en) 2011-07-31
EP2082747A2 (en) 2009-07-29
DK1623719T3 (da) 2009-11-09
JP2006525288A (ja) 2006-11-09
ES2246105B1 (es) 2007-03-01
ES2246178A1 (es) 2006-02-01
PT2356996E (pt) 2013-08-23
PL2356996T3 (pl) 2013-09-30
ES2246105A1 (es) 2006-02-01
DE602004021797D1 (de) 2009-08-13
ES2246178B1 (es) 2007-03-01
DK2356996T5 (da) 2013-08-26
AU2011200170B2 (en) 2011-09-01
IL207875A0 (en) 2011-07-31
IL207877A (en) 2013-03-24
ES2423281T3 (es) 2013-09-19
IL207881A0 (en) 2011-07-31
EP2075007A2 (en) 2009-07-01
EP2356996B1 (en) 2013-06-26

Similar Documents

Publication Publication Date Title
RU2385161C2 (ru) Способ лечения болезни альцгеймера
AU2011226926A1 (en) Alzheimer's disease treatment method

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner